Author Archives: Patricia Inacio PhD

Dosing Begins in Phase 1 Trial of AP-472, for Dyskinesia With Levodopa

A Phase 1 trial of AP-472, Appello Pharmaceutical‘s lead investigational therapy to ease levodopa-induced dyskinesia in Parkinson’s disease, has started dosing healthy adults. The study will randomly assign young, middle-aged, and elderly adults to escalating doses of AP-472 or a placebo. It aims to evaluate the therapy’s safety, tolerability, and…

Financing Supports Planned US Trial of Lecigon for Advanced Parkinson’s

Intrance Medical Systems has raised $8 million to support a planned U.S. clinical trial of its fixed-dose combination of levodopa, carbidopa, and entacapone in advanced Parkinson’s disease patients. The combo therapy, originally developed by Lobsor Pharmaceuticals and sold under the name Lecigon in Nordic countries —  Denmark, Finland, Iceland, Norway and Sweden, and their…

Analyses: Gocovri Works Better to Lessen Off Episodes, Dyskinesia

Several new clinical trial data analyses support the benefits and superiority of Gocovri (amantadine) over other therapies in lessening off episodes — periods when levodopa treatments stop working and motor symptoms return — and involuntary movements called dyskinesia in people with Parkinson’s disease. These analyses compared Gocovri, marketed by…

$75M Funding Will Help TreeFrog Develop Stem Cell Therapies

TreeFrog Therapeutics has raised $75 million in financing to support the clinical development of its stem cell-derived cell therapies for Parkinson’s disease, the company said in a press release. The new financing round, which brings the total funding to date to $83 million, will allow the company to use…

Genetic Testing Costly, Hard to Access, Survey Shows

High prices, lack of access, and long waiting times are major barriers to people who want to undergo genetic testing for Parkinson’s disease, according to a survey by the International Parkinson and Movement Disorder Society (MDS). Survey results will be presented at the MDS Virtual Congress 2021, held…

No Need for Nausea Treatment for Most Patients on Kynmobi

The majority of Parkinson’s patients given Sunovion‘s Kynmobi (apomorphine hydrochloride) for “off” episodes during Phase 3 clinical trials did not require additional treatment for vomiting or nausea, the company said. Indeed, an analysis found that nearly 90% of participants reached the optimal dose of Kynmobi in trials without…

Ask an expert survey graphic

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums